Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Participants with chronic HBV infection will receive multiple doses of ARC-520 in combination
with entecavir or tenofovir and be evaluated for safety and efficacy.